Q-omics provides the consensus-scored FAM86B3P profile across patient tissues and cancer cell-line models. FAM86B3P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, FAM86B3P is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, FAM86B3P RNA expression shows 18,601 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, KICH, and ACC as cancer lineages where FAM86B3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM86B3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM86B3P survival associations across molecular data types. FAM86B3P RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM86B3P RNA expression–survival associations across cancer types. High FAM86B3P expression shows unfavorable associations in ACC, LGG, THCA and UCS, but favorable associations in BRCA and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for FAM86B3P RNA expression.
This table summarizes FAM86B3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for FAM86B3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM86B3P shows lower tumor expression in KICH and higher tumor expression in KIRP, COAD, HNSC, CHOL and READ. The KICH box plot shows higher FAM86B3P RNA expression in normal versus tumor tissue (log2 FC = −0.795, t-test p < 0.001).
This table shows molecular features associated with FAM86B3P in patient tissues and cancer cell lines. In patient samples, FAM86B3P shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM86B3P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST.
